OBJECTIVE: To determine annual biologic drug and administration costs to the US @entity283 ( @entity283 ) per treated @entity1 with @entity309 ( @entity309 ), @entity1569 ( @entity1569 ), @entity5144 ( @entity5144 ), or @entity1691 ( @entity1691 ) who received abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab, or ustekinumab. METHODS: Adults with at least one biologic claim between January 1, 2008 and December 31, 2011 were included. Evidence of enrollment in the @entity283 was required from 365 days before (pre-index) to 360 days after (post-index) the date of the first biologic claim (index date). Included @entity1 had pre-index diagnoses of @entity309 , @entity1569 , @entity5144 , and/or @entity1691 . Drug costs were from Federal Supply Schedule or 'Big Four' in November 2014. Administration costs were @entity283 fixed costs for infused ( 169) and subcutaneous ( 25) biologics. RESULTS: Of the 20,465 @entity1 in the analysis, 10,711 received etanercept, 7838 received adalimumab, and 1196 received infliximab as the index biologic. In these @entity1 , across all uses studied, the @entity283 incurred greater annual cost per treated @entity1 for infliximab ( 18,066) compared with adalimumab ( 16,523) and etanercept ( 16,526). In the first year post-index,    80% of @entity1 were either persistent on these index biologics or re-started these index biologics after a >= 45-day treatment gap. Other biologics comprised <5% of the study population, with sample sizes ranging from 3-374 @entity1 each. Cost by indication for biologics used by >20 @entity1 ranged from  15,056 (etanercept) to  17,050 (abatacept) for @entity309 ;  16,697 (adalimumab) to  33,163 (ustekinumab) for @entity1569 ;  15,035 (etanercept) to  20,465 (infliximab) for @entity5144 ; and  14,239 (etanercept) to  18,536 (infliximab) for @entity1691 . LIMITATIONS: The model was limited to the @entity283 . Results for biologics other than adalimumab, etanercept, and infliximab were difficult to interpret because of small sample sizes. CONCLUSIONS: Infliximab has higher cost to the @entity283 than adalimumab or etanercept.

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis', 'PsO'] @entity283 :: ('OMIM:603663', 'Disease') :: ['Veterans Health Administration', 'VHA'] @entity5144 :: ('MESH:D015535', 'Disease') :: ['PsA', 'psoriatic arthritis'] @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis', 'AS'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']
